‘Report Predicts Chinese Pharma Market Will Reach $116.8bn in 2015′ Says visiongain Report

LONDON, December 7, 2011 -

www.visiongain.com/Report/726/Chinese-Pharmaceutical-Market-2012-2022

A new report by visiongain, a London-based business information company, predicts sustained double-digit growth in the Chinese pharmaceutical market from 2011. National healthcare reforms will stimulate sales of drugs there. Overall pharma revenues gained in China will rise to $116.8bn in 2015, increasing to 2022. That analysis appears in Chinese Pharmaceutical Market 2012-2022, published in December 2011.

In 2010, the overall Chinese pharmaceutical market generated $53.3bn, nearly a quarter of which came from anti-infective drugs. With China’s chronic disease burden increasing, and its population ageing, revenue from 2012 to 2022 will increasingly come from treatments for cancer, cardiovascular and cerebrovascular diseases, diabetes and central nervous system (CNS) disorders. Sales of vaccines will also contribute to the overall growth, the study also notes.

Dr James Evans, a pharmaceutical industry analyst, said: “In recent years, China has been the best hope for the pharmaceutical industry, as thinning R&D pipelines, patent expiries and regulatory tightening leave growth in the developed markets slow at best and sclerotic at worst. With the healthcare reforms in China enlarging the market, the country is no longer a hope but a certainty for the medical industries. Every leading company is outsourcing operations to China, building contacts, partnerships and infrastructure, and adjusting its portfolio to that country. The main question is whose business activities will pay off best this decade.”  

The Chinese government’s 2008 announcement of a programme to reform public healthcare is unprecedented, according to some industry figures. Its Healthy China 2020 plan will mean up to $1.4 trillion invested by 2020, surpassing even US spending on healthcare reforms. In the report, visiongain predicts the effects of rising purchase power and widening medical coverage on revenues from medicines.

In particular, the new study forecasts how pharma submarkets will perform to 2022. It predicts sales of patented brands, generics, OTC products, traditional medicines, anti-infectives, vaccines, cardiovascular/cerebrovascular, alimentary/metabolic, cancer and CNS treatments. The report discusses domestic companies such as China National Biotec Group, Sinopharm, WuXi AppTec, Beijing Pharmaceutical Group and Sinovac Biotech. It also describes activities of multinationals, including Pfizer, Sanofi, Bayer, AstraZeneca, Roche, Novartis, GSK, Merck, Eli Lilly and Novo Nordisk. Medical R&D and drug manufacturing in China are gaining prominence. Chinese Pharmaceutical Market 2012-2022 adds to visiongain’s wide range of analytical research on emerging industries and markets in healthcare.  

To view sample pages please click on:

www.visiongain.com/Report/726/Chinese-Pharmaceutical-Market-2012-2022

Please contact Sara Peerun for an exec summary:
Email: sara.peerun@visiongainglobal.com
Tel: +44(0)20-7336-6100

1. Executive Summary
1.1 China: Pharmaceutical Market Review
1.2 Contents of this Report 
1.3 Research and Analysis Methods

2. Chinese Pharmaceutical Market: An Overview
2.1 China: National Overview
2.1.1 China’s Rise as an Economic Superpower
2.2 From Maoism to Market: Chinese Healthcare Since World War II
2.2.1 Socialised Healthcare
2.2.2 Developments Since 1992
2.2.3 Investment, But Healthcare Disparities Remain
2.3 The Rise of the Chinese Pharmaceutical Market
2.3.1 Picking up the Tab
2.4 Healthy China 2020: ‘Unprecedented in Human History’
2.4.1 Achievements and Potential of the Healthy China 2020 Initiative
2.5 Demography and Disease Burden in China
2.5.1 The Ageing Population
2.5.2 Obesity in China
2.5.3 Stroke, Heart Disease and Diabetes
2.5.4 Cancer and Respiratory Diseases
2.5.5 Communicable Diseases
2.6 Other Aspects of the Chinese Market

3. The Chinese Pharmaceutical Market, 2012-2022
3.1 Chinese Pharmaceutical Market: Forecast, 2012-2022
3.2 The Product Mix in China, 2010
3.3 The Product Mix in China, 2012-2022
3.4 Prescribed Patented Brands: Forecast, 2012-2022
3.4.1 Drivers and Restraints for Patented Prescription Drugs
3.5 Prescribed Generics: Forecast, 2012-2022
3.5.1 Drivers and Restraints for Prescribed Generics
3.6 OTC Products: Forecast, 2012-2022
3.6.1 Drivers and Restraints for OTC Products
3.7 TCM Products: Forecast, 2012-2022
3.7.1 Drivers and Restraints for TCM Products

4. Leading Therapeutic Areas in the Chinese Market, 2012-2022
4.1 Anti-Infectives Market, 2012-2022
4.1.1 Antibiotics: China’s Drugs of Choice
4.1.2 Antivirals: a Growth Area 
4.2 Cancer Treatments Market, 2012-2022
4.2.1 Small Molecules Dominate the Chinese Cancer Drug Market
4.3 Cardiovascular/Cerebrovascular Market, 2012-2022
4.3.1 Anti-Aggregants, Statins and Vasotherapeutics
4.4 Alimentary and Metabolic Diseases Market, 2012-2022
4.4.1 Antiulcerants and Diabetes Treatments
4.5 Central Nervous System Diseases Market, 2012-2022
4.5.1 Pain Relief
4.5.2 Anti-Depressants
4.5.3 Neurodegenerative Diseases
4.6 Vaccines Market, 2012-2022
4.6.1 Opportunities and Challenges in Vaccines 
4.7 Other Therapeutic Classes Market, 2012-2022

5. China as a Pharmaceutical Hub, 2012-2022
5.1 China as a Manufacturing Hub
5.1.1 China’s API Export Market
5.1.2 Contract Manufacturing Organisations: Beyond APIs
5.2 China as a Research Hub
5.2.1 Clinical Trials in China
5.2.2 The Rise of China’s Contract Research Organisations
5.3 China as a Biotechnology Hub
5.3.1 Leading the Way in Biosimilars
5.3.2 Biomarkers and Genomic Sequencing
5.3.3 Stem Cells in China
5.3.4 Other Regenerative Medicine in China
5.4 China as a Pharmaceutical Hub: Conclusions

6. Key Domestic Players in the Chinese Market, 2012
6.1 Fragmentation and Consolidation Among Chinese Companies
6.2 Summary of Leading Domestic Companies
6.3 China National Pharmaceutical Corporation (Sinopharm)
6.4 China National Biotec Group (CNBG)
6.5 WuXi AppTec
6.6 CSPC Pharmaceutical Group
6.7 Beijing Pharmaceutical Group
6.8 Shanghai Pharmaceutical Group (SPGC)
6.9 Yangtze River Pharmaceutical Group
6.10 Tianjin Pharmaceuticals Group Corporation (TJPC)
6.11 Taiji Group
6.12 C&O Pharmaceutical Technology Holdings
6.13 Harbin Pharmaceutical Group Holding Company
6.14 Guangzhou Pharmaceutical Holdings
6.15 Sinovac Biotech (Beijing Kexing Bioproducts)
6.16 Tongrengtang Pharmaceutical
6.17 Buchang Pharmaceutical
6.18 Northeast Pharmaceutical Group (NEPG)
6.19 China Nepstar Chain Drugstore
6.20 Zhejiang Huahai Pharmaceuticals
6.21 Hangzhou Zhongmei Huadong Pharmaceutical
6.22 Hualan Biological Engineering
6.23 China Sky One Medical
6.24 Zensun (Shanghai) Sci & Tech
6.25 Ascletis
6.26 Shangdong Dong-E-E-Jiao
6.27 Mindray Medical International and China Medical Technologies

7. Key Multinational Players in the Chinese Market, 2012
7.1 Bayer Schering
7.2 AstraZeneca
7.3 Pfizer
7.4 Sanofi
7.5 Roche
7.6 Novartis
7.7 GlaxoSmithKline
7.8 Merck & Co.
7.9 Novo Nordisk
7.10 Eli Lilly
7.11 Abbott Laboratories
7.12 Johnson & Johnson
7.13 Bristol-Myers Squibb
7.14 Teva Pharmaceutical Industries
7.15 Takeda

8. The Chinese Pharma Market: Qualitative Analysis
8.1 Strengths: Government Investment Will Further Expand this Dynamic Market
8.2 Weaknesses: IP and Regulatory Challenges Remain
8.3 Opportunities: The Scramble for China
8.4 Threats: A House Built on Sand?

9. Research Interviews 
9.1 Interview with Dr Derek Lowe, Drug Discovery Expert
9.1.1 On the Rising Cost of Outsourcing Research to China
9.1.2 On Building Relationships in the Chinese Market
9.1.3 On Prospects for Western Brands in the Chinese Market
9.1.4 On IP Protection and Safety Concerns in China
9.1.5 On the Role of the Chinese State in the Pharmaceutical Market
9.1.6 On Biotechnology and the Chinese Research Culture
9.1.7 On Chinese Biosimilar Manufacturing
9.2 Interview with Dr Jean-Pierre Wery, President, Crown Bioscience, China
9.2.1 Contract Research Services Offered by Crown Bioscience
9.2.2 On Technological Platforms and Animal Models Relevant to Biomarkers
9.2.3 On the Range of Therapeutic Areas Covered by Crown Bioscience
9.2.4 On Translational Medicine and Patient Stratification
9.2.5 On the Future for Crown Bioscience and Other CROs

10. Conclusions
10.1 The Chinese Pharma Market Will Continue to Grow Rapidly
10.2 Treatments for Chronic Diseases Will Challenge the Anti-Infectives Sector
10.3 China Will Continue to Grow as a Focus for the Multinational Industry
10.4 China is Set to be the Most Important Pharmaceutical Market, Despite Weaknesses

Companies Listed

Abbott Laboratories
Acambis
Agilent Technologies
American California Pharmaceutical Group
Anhui BBCA Biochemical
AppTech Laboratory Services
Ascletis
Asian Cancer Research Group
AstraZeneca
Aurobindo Pharma
AXM Pharma
Bayer Schering Pharma
Beijing Bio-Ekon Biotechnology
Beijing Double-Crane Pharmaceutical Business
Beijing GP Medical Technologies
Beijing Haiyan Pharmaceutical Company
Beijing Pharmaceutical Group
Beijing Shuanglu
Beijing Tiantan Biological Products
Beijing Union Medical College Hospital
Beijing University
Beijing Wandong Medical Equipment
Beijing Yuande Bio-Medical Engineering
BGI (formerly Beijing Genomics Institute)
Biocon
BioDura
BioMarin Pharmaceutical
Bioton
BMP Sandstone
Bristol-Myers Squibb
Broad Institute
Buchang Pharmaceutical
C&O Pharmaceutical Technology Holdings
Cai Zhi Lin Pharmacies
Cancer Therapeutics
Charles River Laboratories
China Aoxing
China Chain Stores and Franchise Association (CCSFA)
China Medical Technologies
China National Biotec Group
China National Pharmaceutical Corporation (Sinopharm)
China Nepstar Chain Drugstore
China Pharmaceutical Group (China Pharma)
China Sky One Medical
ChinaBio Therapeutics
Chinese Academy of Medical Sciences
Chinese Academy of Sciences
Chinese Diabetes Society
Chongqing Taiji Industry Group
Chongqing Tongjunge
Cipla
Cord Blood America
Covance
Crown Bioscience
Crucell Biotechnology
CSPC Pharmaceutical Group
CSPC Zhongrun
Cumencor Pharmaceuticals
Denosim
Dong-A Pharmaceutical
Dr. Reddy’s Laboratories
Eisai
Eli Lilly
European Medicines Agency (EMEA/EMA)
Excel PharmaStudies
FeRx
Food and Drug Administration (FDA, US)
Frontage Laboratories
GenScript
Genzyme Corporation
GlaxoSmithKline
Goldman Sachs Group
Greater China Corporation
Guangdong Province People’s Hospital
Guangzhou Medical University
Guangzhou Pharmaceutical Company
Guangzhou Pharmaceutical Holdings
Habin Tian Di Ren Medical Science and Technology
Hangzhou Sanofi-Synthelabo Minsheng
Hangzhou Zhongmei Huadong Pharmaceutical
Harbin Pharmaceutical Group
HD Biosciences
Hebei Pharmaceutical Group
Huadong Medicine Company
Hualan Biological Engineering
Hutchison MediPharma
Institute for BioMedical Research (Shanghai)
International Diabetes Foundation
Introgen Therapeutics
Ivax Corporation
Jian Min Pharmacies
Jiangsu Haici Biological Pharmacy Company
Jiangsu New Medicine Research Institution
Jiangsu Walvax Biotech
Johnson & Johnson
Knoll
LEAD Pharmaceuticals
LG Life Sciences
Lundbeck
Merck & Co.
MicuRx Pharmaceuticals
Mindray Medical International
Ministry of Commerce (China)
Ministry of Science and Technology (China)
Minsheng Pharmaceutical
Mirahi Biotech
Nanjing Hailing National Engineering Research Center
Nanjing Hailing Pharmaceutical Company
National Center for Drug Screening (China)
New England Journal of Medicine
Northeast General Pharmaceutical
Northeast Pharmaceutical Group (NEPG)
NorthEast Pharmacy Chain
NovaMed Pharmaceuticals
Novartis
Novartis China
Novo Nordisk
Nycomed Amersham
Organization for Economic Cooperation and Development (OECD)
Patheon
Pfizer
Piramal Healthcare Solutions
PlaNrt Finance
Provincial Institute for the Control of Pharmaceutical and Biologic Products (China)
Qilu Pharmaceutical
QRxPharma
Roche
Sandoz (part of Novartis)
Sanjing Pharmaceutical
Sanofi
Shandong Dong-E E-Jiao
Shanghai Zhong Hua Pharmaceutical Factory (Jiang Qiao Branch)
Shanghai ChemExplorer
Shanghai Haini Pharmaceutical Company
Shanghai Huai Hai Pharmaceutical Factory
Shanghai Institute for Biological Sciences
Shanghai Institute of Materia Medica
Shanghai Jiao Tong University
Shanghai No. 6 Pharmaceutical Factory
Shanghai Pharmaceutical Group (SPGC)
Shanghai Qisheng
Shanghai Schering-Plough
Shanghai Sunve Pharmaceutical
Shanghai Xin Hua Lian Pharmaceutical
Shenzhen Neptunus Interlong Bio-Technique
Shenzhen SiBiono GeneTech
Shijiazhuang Pharmaceutical Group
Shire Pharmaceuticals
SiBiono
Sichuan Hairong Pharmaceutical Company
Sicor Pharmaceuticals
SiniWest Holdings
Sino-American Kunming Baker Norton Pharmaceutical
Sinopharm
Sinovac Biotech (Beijing Kexing Bioproducts)
Solvay Pharmaceuticals
Southwest Pharmaceutical
State Food and Drug Administration (SFDA)
State Key Lab of Respiratory Disease
Sundia Meditech
Sunway Biotech
Suzhou Novartis Pharma Technology
Taiji Group
Takeda Pharmaceutical
Tangshan Yian Bioengineering
Teva Pharmaceutical Industries
Thermo Fisher Scientific
Tianjin International Joint Academy of Biotechnology and Medicine
Tianjin Jin Yao Group
Tianjin Medical University Cancer Hospital
Tianjin Pharmaceutical Factory
Tianjin Pharmaceuticals Group Corporation
Tianjin Takeda Pharmaceuticals
Tonghua Dongbao
Tongrentang Pharmaceutical
Tsinghua University
UNICEF
United Pharmatech
Vertex Pharmaceuticals
Weisheng Pharmaceutical
Working Group on Obesity in China
World Health Organization (WHO)
World Trade Organization (WTO)
Wuhan National Bioindustry Base Construction
WuXi AppTec
WuXi PharmaTech
Wyeth (now part of Pfizer)
Xian-Janssen Pharmaceuticals
Yangtze River Pharmaceutical Group
Yunnan Walvax BiotechJiangsu Pharmaceutical Company
Zensun (Shanghai) Sci & Tech
Zhejiang Huahai Pharmaceuticals
Zhejiang Medicine
Zhejiang Tianyuan
Zhongnuo
Zydus Cadila

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100

.